Login to Your Account



Financings Roundup


Friday, December 17, 2010
• Provesica Ltd., of Cambridge, UK, received £4 million (US$6.2 million) from Forbion Capital Partners and Seroba Kernal Life Sciences Ltd. to advance its overactive bladder program through to the completion of a Phase II trial in 2011.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription